VENUS MEDTECH (HANGZHOU) INC. Financials Venus Medtech (Hangzhou) Inc.
Equities
2500
CNE100003PJ8
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.62 HKD | -0.71% |
|
-.--% | -.--% |
| Apr. 01 | Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% | MT |
| Mar. 28 | Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,555 | 28,141 | 10,561 | 5,515 | 2,258 | 2,258 | - |
| Enterprise Value (EV) 1 | 11,288 | 25,422 | 7,611 | 4,432 | 2,258 | 2,383 | 2,721 |
| P/E ratio | -27.5 x | -148 x | -28.4 x | -5.2 x | -3.13 x | -7.89 x | -56.5 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 58.1 x | 102 x | 25.4 x | 13.6 x | 4.6 x | 3.09 x | 2.28 x |
| EV / Revenue | 48.4 x | 92.1 x | 18.3 x | 10.9 x | 4.6 x | 3.26 x | 2.75 x |
| EV / EBITDA | -37.7 x | -180 x | -33.5 x | -8 x | -4.79 x | -21.8 x | 27.2 x |
| EV / FCF | -34.4 x | -70.4 x | -13.6 x | - | -3.86 x | -4.91 x | -13.9 x |
| FCF Yield | -2.9% | -1.42% | -7.34% | - | -25.9% | -20.4% | -7.2% |
| Price to Book | 3.43 x | 7.22 x | 2.32 x | - | 0.74 x | 0.93 x | 0.93 x |
| Nbr of stocks (in thousands) | 404,469 | 422,969 | 437,897 | 437,897 | 437,897 | 437,897 | - |
| Reference price 2 | 33.51 | 66.53 | 24.12 | 12.59 | 5.157 | 5.157 | 5.157 |
| Announcement Date | 3/27/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 115.3 | 233.3 | 276 | 415.9 | 406.5 | 491.4 | 730.2 | 990.1 |
| EBITDA 1 | - | -299.1 | -140.9 | -227 | -553.7 | -471.9 | -109.2 | 100 |
| EBIT 1 | - | -328 | -178.6 | -278.6 | -666 | -596.7 | -312.1 | 41.15 |
| Operating Margin | - | -140.63% | -64.7% | -67% | -163.86% | -121.44% | -42.74% | 4.16% |
| Earnings before Tax (EBT) 1 | - | -381.5 | -185.8 | -377.6 | -1,156 | -752.5 | -328.4 | 47.2 |
| Net income 1 | - | -380.7 | -182 | -373.6 | -1,058 | -720.9 | -293.5 | 38.5 |
| Net margin | - | -163.21% | -65.93% | -89.85% | -260.22% | -146.71% | -40.19% | 3.89% |
| EPS 2 | - | -1.220 | -0.4500 | -0.8500 | -2.420 | -1.650 | -0.6533 | -0.0913 |
| Free Cash Flow 1 | - | -327.8 | -361.1 | -558.7 | - | -479.3 | -485 | -196 |
| FCF margin | - | -140.53% | -130.79% | -134.35% | - | -84.98% | -66.42% | -19.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 11/27/19 | 3/27/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 107.4 | 147.1 | 102 | 174 | 239.3 | 176.6 | 210 | 196.5 | 255.6 | 235.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | -60.08 | -218.6 | -234.2 | -431.8 | -329.3 | -267.5 |
| Operating Margin | - | - | - | - | -25.11% | -123.77% | -111.54% | -219.77% | -128.82% | -113.45% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | -0.2600 | -0.5900 | -0.4600 | -1.960 | -0.8000 | -0.8500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | - | 3/27/20 | 8/28/20 | 3/31/21 | 8/31/21 | 3/31/22 | 8/31/22 | 3/31/23 | 8/31/23 | 3/28/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 125 | 463 |
| Net Cash position 1 | - | 2,267 | 2,720 | 2,950 | 1,083 | 410 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -1.146 x | 4.628 x |
| Free Cash Flow 1 | - | -328 | -361 | -559 | - | -479 | -485 | -196 |
| ROE (net income / shareholders' equity) | - | -21.8% | -5.07% | -8.94% | -25.4% | -18.6% | -16% | 2.4% |
| ROA (Net income/ Total Assets) | - | -16.2% | -4.35% | -7.93% | -19.9% | -12.1% | -9% | 1.6% |
| Assets 1 | - | 2,352 | 4,180 | 4,714 | 5,303 | 4,745 | 3,261 | 2,406 |
| Book Value Per Share 2 | - | 9.760 | 9.220 | 10.40 | - | 6.940 | 5.540 | 5.550 |
| Cash Flow per Share 2 | - | -0.9800 | -0.5800 | -1.040 | - | -0.7400 | - | - |
| Capex 1 | - | 24.5 | 124 | 102 | - | 229 | 353 | 378 |
| Capex / Sales | - | 10.52% | 44.94% | 24.47% | - | 40.66% | 48.34% | 38.18% |
| Announcement Date | 11/27/19 | 3/27/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
5.157
CNY
Average target price
7.414
CNY
Spread / Average Target
+43.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 314M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- 2500 Stock
- Financials Venus Medtech (Hangzhou) Inc.
